EAU Podcasts

In this special edition of EAU Podcasts, experts Prof. Paolo Gontero and Prof. Alexandra Masson-Lecomte met in person at the EAU Annual Congress (EAU24) to discuss the newest updates to the EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma (UTUC). Panel Chairs Prof. Paolo Gontero and Prof. Alexandra Masson-Lecomte cover points of change in the UTUC guidelines, including genetic testi...

In 'Episode 3' of the series “What young urologists need to know" , titled "Mentorship and peer support: Navigating urology together” , Prof. Prokar Dasgupta (GB) and Assoc. Prof.  Juan Luis Vásquez (DK) talk about the crucial role of mentorship and peer support in the field of urology. They discuss how guidance from experienced mentors and collaboration among peers can enhance...

Tune in to 'Episode 2' of the series “What young urologists need to know" , titled "Academic - clinics balance: How to achieve it?" , where Prof. Bhaskar Somani (GB) and Ass. Prof. Giorgio Gandaglia (IT) navigate the delicate equilibrium between academia and clinical practice in urology. In their discussion they share insightful strategies and personal experiences on balan...

In 'Episode 1' of the series on "What young urologists need to know" , segment 2 covers the topic of "Balancing the life of a young urologist" . Dr. Thomas Tailly (BE) and Dr. Michiel Sedelaar (NL) offer a comprehensive exploration of the age-old question: Is it truly possible to strike a balance between work and well-being?   Dr. Tailly and Dr. Sedelaar delve into th...

In 'Episode 3', the final of the series on " Metastatic renal cell carcinoma ", Dr. Andrea Mari (IT) talks with Dr. Chiara Ciccarese (IT) from the Medical Oncology Unit at Fondazione Policlinico Universitario A. Gemelli IRCCS, in Rome. Together they have an in-depth discussion on " Beyond first-line treatment strategies for metastatic renal cell carcinoma ". Dr. Mari...

In 'Episode 2' of the series on " Metastatic renal cell carcinoma ", Dr. Andrea Mari (IT) talks to Dr. Laura Marandino (GB) about " The first-line treatment strategies for metastatic renal cell carcinoma ". Dr. Andrea Mari and Dr. Laura Marandino unravel the complexities of mRCC management, exploring the latest advancements, therapeutic options, and their implications...

UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to Prof. Christophe Hennequin from Saint-Louis Hospital, France about the GETUG-AFU 18 trial results he presented at ASCO GU24 in San Francisco. Prof. Hennequin shares details on the design of the study, followed by the trial results of long-term dose escalation (80 vs 70Gy) combined with long-term androgen deprivation in high-risk pro...

In 'Episode 1' of a series on " Metastatic renal cell carcinoma ", Assist. Prof. Andrea Mari (IT) and Prof. Ketan Badani (US) discuss " The role of cytoreductive nephrectomy for metastatic renal cell carcinoma ". Assist. Prof. Andrea Mari and Prof. Ketan Badani delve into the pivotal role of cytoreductive nephrectomy in the management of metastatic renal cell carcinom...

In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Prof. Michael Hofman from the Peter MacCallum Cancer Centre, Australia, on the results of his study “First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC)”.  Prof. Hofman discusses the data he presented at ASCO GU24 in San F...

In this podcast, UROONCO RCC chief editor Dr. Carmen Mir interviews Prof. Nizar Tannir from the University of Texas, MD Anderson Cancer Center, USA, on the long-term follow-up data from the phase 3 CheckMate 214 trial: Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC).   Prof. Tannir summarises the history and stability of the...

In this podcast interview live from ASCO GU24 in San Francisco, UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to medical oncologist Dr. Kim Chi from the University of British Columbia, Canada, about the CONTACT-2 trial. This randomised phase 3 trial aimed to evaluate the efficacy of cabozantinib + atezolizumab vs. second novel hormonal therapy in patients with metastatic castratio...

In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Assoc. Prof. Pedro Barata from University Hospitals Seidman Cancer Center, USA, about the results of two adjuvant RCC studies: KEYNOTE-564; and CheckMate-914. Assoc. Prof. Barata explains the positive trial results of KEYNOTE-564, which is the first time there has been an overall survival advantage with a PD-1 inhibitor in th...

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews medical oncologist Dr. Andrea Apolo from the National Cancer Institute, USA, on the results of the AMBASSADOR study, which she presented at ASCO GU24.   Dr. Apolo shares details on the rationale of the AMBASSADOR study: An open-label, randomised, phase III trial, evaluating the efficacy and safety of pembrolizumab as an...

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Srikala Sridhar (CA), about her abstract she recently presented at ESMO 2023, PET-MUSE: “Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC)”. Dr. Sridhar shares details on the rationale and design of the study, as well as some interesting results. For more detail...

In this edition, Dr. Aisling Nic an Riogh (IE), a member of the EAU Guidelines panel for Non-neurogenic female LUTS, discusses bladder outlet obstruction (BOO) in women. Dr. Nic an Riogh defines bladder outlet obstruction, its prevalence, and the various symptoms. She further explains that BOO can be divided into two main groups, anatomical (physical or mechanical), and functional (non-anatomical,...

In this podcast, UROONCO RCC board members, chief editor Dr. Carmen Mir (ES), and associate editors Dr. Riccardo Bertolo (IT) and Dr. Teele Kuusk (GB), discuss the progress made in the field of kidney cancer during 2023, and what is anticipated for 2024. Some topics discussed include the game-changing ZIRCON trial, OpeRa trial, and 3D models in PN and single-port RPN, as well as SBRT – FASTRACK II...

In 'Episode 4' of the series " What do young urologists need to know , " 'Segment 1' covers the topic of " Navigating the transition from residency to professional urology practice. " Assoc. Prof. Emre Şener (TR) discusses networking and building professional relationships in urology with Dr. Amelia Pietropaolo (GB). Assoc. Prof. Şener and Dr. Pietropaolo de...

This is 'Episode 3' of the podcast series " What do young urologists need to know ," 'Segment 1': " Navigating the transition from residency to professional urology practice . " Dr. Elena Seguí-Moya (GB) converses with Prof. Sabine Brookman-May (US) about preparing for a job interview . The discussion highlights essential steps and strategies for excelling i...

In 'Episode 2' of the series on " What young urologists need to know , " segment 1 covers the topic of " Navigating the transition from residency to professional urology practice . " Dr. Bhavan Prasad Rai (GB) and Dr. Guido Kamphuis (NL) delve into the aspects of preparing and maintaining an effective CV . Dr. Rai and Dr. Kamphuis talk about how your CV should highlig...

In 'Episode 1' of the series on " What young urologists need to know, " segment 1 covers the topic of " Navigating the transition from residency to professional urology practice. " Assoc. Prof. Veeru Kasivisvanathan (GB) and Ms. María Pilar Moreno-Fontela (ES) discuss the significant transition from residency to independent practice in this episode titled: " My r...

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. James Catto (GB) about the THOR-2 cohort 1 study: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment....

In this podcast, Dr. Neeraj Agarwal (US), presidential endowed chair of cancer research at the Huntsman Cancer Institute, University of Utah, shares the results of the LITESPARK-013 Phase 2 trial - "Safety and efficacy of two doses of belzutifan in patients with advanced renal cell carcinoma", that he presented at ESMO 2023.  Firstly, Dr. Agarwal shares the rationale of the study, which...

In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with Prof. Roberto Iacovelli (IT), Gostino Gemelli University Polyclinic, Rome, about the abstract he presented at ESMO 2023, "The TIDE-A study: Phase II study of avelumab (Ave) plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma".   Prof. Iacovelli shares details on the...

In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with medical oncologist Prof. Laurence Albiges (FR), Head of the Department of Oncology at Gustave Roussy, about her abstract: Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomised open-label phase III LITESPARK-005 study. Prof. Albiges discusses the...

In this podcast from ESMO 2023, UROONCO BCa associate editor Dr. Laura Mertens (NL) talks with Dr. Michiel Van Der Heijden (NL) on his abstract “Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial”. Dr. Van Der Heijden shares details on the design of the trial...